Pneumococcal infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pneumococcal infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-v116-vaccine-for-pneumococcal-disease-in-adults-aged-50-and-older/ Wed, 29 Apr 2026 15:05:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-v116-vaccine-for-pneumococcal-disease-in-adults-aged-50-and-older/ This clinical trial is focused on studying a disease called pneumococcal disease, which is caused by bacteria that can lead to infections in the lungs, blood, and brain. The study is testing a new vaccine called the Pneumococcal 21-valent Conjugate Vaccine, also known by its code name V116. This vaccine is designed to protect against 21 different types of the bacteria that cause pneumococcal disease. The study will compare the effects of V116 with another vaccine called PPSV23, which is already used to prevent pneumococcal disease.

The purpose of the study is to evaluate the safety and effectiveness of V116 in adults aged 50 years or older who have not previously received a pneumococcal vaccine. Participants will receive an injection of either V116 or PPSV23. The study will monitor participants for any side effects and measure their immune response to the vaccine. This will help determine how well the vaccine works in producing antibodies, which are proteins in the blood that help fight infections.

Participants will be followed for a period of time to observe any reactions to the vaccine and to measure the levels of antibodies in their blood. The study aims to see if V116 can provide better protection against pneumococcal disease compared to the existing vaccine. The results will help in understanding the potential benefits of using V116 for preventing infections caused by pneumococcal bacteria in older adults.

]]> Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-pf-07831695-and-a-drug-combination-for-pneumococcal-infections-in-healthy-toddlers-aged-12-15-months/ Wed, 29 Apr 2026 15:05:27 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-pf-07831695-and-a-drug-combination-for-pneumococcal-infections-in-healthy-toddlers-aged-12-15-months/ This clinical trial is focused on studying the safety and immune response of a new vaccine candidate in healthy toddlers. The vaccine is designed to protect against Pneumococcal Infections, which are caused by bacteria that can lead to illnesses such as pneumonia, ear infections, and meningitis. The study involves a vaccine known as a Monovalent Pneumococcal Conjugate Candidate, which will be given in two doses to children aged 12 to 15 months who have already received a primary series of another vaccine called PCV10.

The purpose of the study is to observe how the children’s bodies react to the new vaccine. This includes monitoring for any local reactions like redness, swelling, or pain at the injection site, as well as systemic events such as fever, decreased appetite, increased sleepiness, or irritability. The study will also track any adverse events, which are unexpected medical problems that occur during the study, and serious adverse events, which are more severe health issues.

Additionally, the study will measure the levels of Immunoglobulin G (IgG), a type of antibody, and the opsonophagocytic activity (OPA), which is a measure of the vaccine’s ability to help the immune system fight off the bacteria. The trial is expected to provide valuable information on the vaccine’s safety and effectiveness in boosting the immune response in young children.

]]> Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-v116-vaccine-in-children-and-adolescents-at-higher-risk-for-pneumococcal-disease/ Wed, 29 Apr 2026 14:47:44 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-v116-vaccine-in-children-and-adolescents-at-higher-risk-for-pneumococcal-disease/ This clinical trial is focused on studying the safety and effectiveness of a new vaccine called V116 in children and adolescents who are at increased risk of developing pneumococcal disease. Pneumococcal disease is an infection caused by the bacteria Streptococcus pneumoniae, which can lead to serious illnesses like pneumonia, meningitis, and bloodstream infections. The study will compare the new vaccine, V116, with an existing vaccine known as Pneumovax® 23, which is also used to prevent pneumococcal disease.

The purpose of the study is to evaluate how safe and well-tolerated the new vaccine is, as well as how well it works in producing an immune response. Participants in the study will receive either the new vaccine, V116, or the existing vaccine, Pneumovax® 23, or a placebo. The study will monitor participants for any side effects and measure their immune response to the vaccine. This will help determine if the new vaccine is as effective or more effective than the existing one.

Participants will be followed for a period of time to observe any reactions to the vaccine and to measure the levels of antibodies, which are proteins in the blood that help fight infections. The study aims to provide valuable information on the potential benefits of the new vaccine for those at higher risk of pneumococcal disease, such as individuals with conditions like diabetes, chronic lung disease, or chronic heart disease. The results of this study could lead to improved prevention strategies for pneumococcal disease in vulnerable populations.

]]> Study on the V116 Vaccine for Adults Aged 18-64 at Increased Risk of Pneumococcal Infection https://clinicaltrials.eu/trial/study-on-the-v116-vaccine-for-adults-aged-18-64-at-increased-risk-of-pneumococcal-infection/ Wed, 29 Apr 2026 14:24:36 +0000 https://clinicaltrials.eu/trial/study-on-the-v116-vaccine-for-adults-aged-18-64-at-increased-risk-of-pneumococcal-infection/ This clinical trial is focused on studying a disease called Pneumococcal infection, which is caused by bacteria that can lead to serious illnesses like pneumonia, meningitis, and bloodstream infections. The study is testing a new vaccine called V116, which is designed to protect against this infection. The trial will also compare the effects of V116 with other vaccines, specifically PCV15 and PPSV23. Participants in the study will receive either the new vaccine or a placebo, which is a substance with no active ingredients, to help researchers understand the vaccine’s safety and effectiveness.

The purpose of the study is to evaluate how safe and well-tolerated the V116 vaccine is, as well as how well it works in producing an immune response in adults aged 18 to 64 who are at increased risk for pneumococcal disease. This includes individuals with conditions like diabetes, chronic liver disease, chronic obstructive pulmonary disease (COPD), asthma, chronic heart disease, and chronic kidney disease. The study will monitor participants for any side effects and measure their immune response to the vaccine over a period of time.

Participants will be randomly assigned to receive either the V116 vaccine or the other vaccines being studied. They will receive the vaccine through an injection into the muscle. The study will track any reactions at the injection site, as well as any other side effects, for a few days after vaccination. Additionally, the study will measure the levels of specific antibodies in the blood, which are proteins that help fight infections, to see how well the vaccine works in boosting the immune system. The study aims to provide valuable information on the potential benefits of the V116 vaccine for preventing pneumococcal infections in people who are more vulnerable to this disease.

]]>